STOCK TITAN

[Form 4] MiMedx Group, Inc Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

MiMedx Group Director William A. Hawkins acquired 28,609 shares of common stock on June 18, 2025, at a price of $6.47 per share. This transaction represents an annual restricted stock grant to non-employee directors and is exempt under Rule 16b-3.

Following the transaction, Hawkins now beneficially owns a total of 204,018 shares directly. The restricted stock grant will vest upon the earlier of 12 months or the next annual meeting of shareholders.

Key Transaction Details:

  • Transaction Type: Acquisition (Form 4)
  • Stock Type: Common Stock
  • Transaction Value: Approximately $185,100
  • Ownership Form: Direct
  • Filing Date: June 28, 2025

Il Direttore del Gruppo MiMedx, William A. Hawkins, ha acquistato 28.609 azioni di azioni ordinarie il 18 giugno 2025, al prezzo di 6,47 $ per azione. Questa operazione rappresenta una concessione annuale di azioni vincolate ai direttori non dipendenti ed è esente ai sensi della Regola 16b-3.

Dopo la transazione, Hawkins possiede beneficiariamente un totale di 204.018 azioni direttamente. La concessione delle azioni vincolate sarà acquisita al verificarsi del primo evento tra 12 mesi o la prossima assemblea annuale degli azionisti.

Dettagli principali della transazione:

  • Tipo di transazione: Acquisizione (Modulo 4)
  • Tipo di azioni: Azioni ordinarie
  • Valore della transazione: Circa 185.100 $
  • Forma di proprietà: Diretta
  • Data di deposito: 28 giugno 2025

El Director del Grupo MiMedx, William A. Hawkins, adquirió 28,609 acciones de acciones comunes el 18 de junio de 2025, a un precio de $6.47 por acción. Esta transacción representa una concesión anual de acciones restringidas para directores no empleados y está exenta bajo la Regla 16b-3.

Tras la transacción, Hawkins posee beneficiosamente un total de 204,018 acciones directamente. La concesión de acciones restringidas se consolidará al cumplirse el primero de los siguientes eventos: 12 meses o la próxima junta anual de accionistas.

Detalles clave de la transacción:

  • Tipo de transacción: Adquisición (Formulario 4)
  • Tipo de acciones: Acciones comunes
  • Valor de la transacción: Aproximadamente $185,100
  • Forma de propiedad: Directa
  • Fecha de presentación: 28 de junio de 2025

MiMedx 그룹 이사 William A. Hawkins는 2025년 6월 18일에 28,609주의 보통주를 주당 $6.47에 취득했습니다. 이 거래는 비임원 이사에게 연간 제한 주식 부여를 의미하며, 규칙 16b-3에 따라 면제됩니다.

거래 후 Hawkins는 총 204,018주를 직접 실질 소유하고 있습니다. 제한 주식 부여는 12개월 후 또는 다음 연례 주주총회 중 빠른 시점에 권리가 확정됩니다.

주요 거래 세부사항:

  • 거래 유형: 취득 (양식 4)
  • 주식 종류: 보통주
  • 거래 금액: 약 $185,100
  • 소유 형태: 직접 소유
  • 제출일: 2025년 6월 28일

Le directeur du groupe MiMedx, William A. Hawkins, a acquis 28 609 actions ordinaires le 18 juin 2025, au prix de 6,47 $ par action. Cette transaction représente une attribution annuelle d'actions restreintes aux administrateurs non salariés et est exonérée en vertu de la règle 16b-3.

Suite à cette transaction, Hawkins détient désormais bénéficiairement un total de 204 018 actions en direct. L'attribution des actions restreintes sera acquise au plus tôt entre 12 mois ou la prochaine assemblée annuelle des actionnaires.

Détails clés de la transaction :

  • Type de transaction : Acquisition (Formulaire 4)
  • Type d'actions : Actions ordinaires
  • Valeur de la transaction : Environ 185 100 $
  • Forme de propriété : Directe
  • Date de dépôt : 28 juin 2025

Der MiMedx-Gruppendirektor William A. Hawkins erwarb am 18. Juni 2025 28.609 Aktien von Stammaktien zum Preis von 6,47 $ pro Aktie. Diese Transaktion stellt eine jährliche Zuteilung von eingeschränkten Aktien an nicht angestellte Direktoren dar und ist gemäß Regel 16b-3 ausgenommen.

Nach der Transaktion besitzt Hawkins nun insgesamt 204.018 Aktien direkt wirtschaftlich. Die Zuteilung der eingeschränkten Aktien wird mit dem früheren von 12 Monaten oder der nächsten Jahreshauptversammlung der Aktionäre fällig.

Wichtige Transaktionsdetails:

  • Transaktionstyp: Erwerb (Formular 4)
  • Aktienart: Stammaktien
  • Transaktionswert: Ca. 185.100 $
  • Eigentumsform: Direkt
  • Einreichungsdatum: 28. Juni 2025
Positive
  • None.
Negative
  • None.

Il Direttore del Gruppo MiMedx, William A. Hawkins, ha acquistato 28.609 azioni di azioni ordinarie il 18 giugno 2025, al prezzo di 6,47 $ per azione. Questa operazione rappresenta una concessione annuale di azioni vincolate ai direttori non dipendenti ed è esente ai sensi della Regola 16b-3.

Dopo la transazione, Hawkins possiede beneficiariamente un totale di 204.018 azioni direttamente. La concessione delle azioni vincolate sarà acquisita al verificarsi del primo evento tra 12 mesi o la prossima assemblea annuale degli azionisti.

Dettagli principali della transazione:

  • Tipo di transazione: Acquisizione (Modulo 4)
  • Tipo di azioni: Azioni ordinarie
  • Valore della transazione: Circa 185.100 $
  • Forma di proprietà: Diretta
  • Data di deposito: 28 giugno 2025

El Director del Grupo MiMedx, William A. Hawkins, adquirió 28,609 acciones de acciones comunes el 18 de junio de 2025, a un precio de $6.47 por acción. Esta transacción representa una concesión anual de acciones restringidas para directores no empleados y está exenta bajo la Regla 16b-3.

Tras la transacción, Hawkins posee beneficiosamente un total de 204,018 acciones directamente. La concesión de acciones restringidas se consolidará al cumplirse el primero de los siguientes eventos: 12 meses o la próxima junta anual de accionistas.

Detalles clave de la transacción:

  • Tipo de transacción: Adquisición (Formulario 4)
  • Tipo de acciones: Acciones comunes
  • Valor de la transacción: Aproximadamente $185,100
  • Forma de propiedad: Directa
  • Fecha de presentación: 28 de junio de 2025

MiMedx 그룹 이사 William A. Hawkins는 2025년 6월 18일에 28,609주의 보통주를 주당 $6.47에 취득했습니다. 이 거래는 비임원 이사에게 연간 제한 주식 부여를 의미하며, 규칙 16b-3에 따라 면제됩니다.

거래 후 Hawkins는 총 204,018주를 직접 실질 소유하고 있습니다. 제한 주식 부여는 12개월 후 또는 다음 연례 주주총회 중 빠른 시점에 권리가 확정됩니다.

주요 거래 세부사항:

  • 거래 유형: 취득 (양식 4)
  • 주식 종류: 보통주
  • 거래 금액: 약 $185,100
  • 소유 형태: 직접 소유
  • 제출일: 2025년 6월 28일

Le directeur du groupe MiMedx, William A. Hawkins, a acquis 28 609 actions ordinaires le 18 juin 2025, au prix de 6,47 $ par action. Cette transaction représente une attribution annuelle d'actions restreintes aux administrateurs non salariés et est exonérée en vertu de la règle 16b-3.

Suite à cette transaction, Hawkins détient désormais bénéficiairement un total de 204 018 actions en direct. L'attribution des actions restreintes sera acquise au plus tôt entre 12 mois ou la prochaine assemblée annuelle des actionnaires.

Détails clés de la transaction :

  • Type de transaction : Acquisition (Formulaire 4)
  • Type d'actions : Actions ordinaires
  • Valeur de la transaction : Environ 185 100 $
  • Forme de propriété : Directe
  • Date de dépôt : 28 juin 2025

Der MiMedx-Gruppendirektor William A. Hawkins erwarb am 18. Juni 2025 28.609 Aktien von Stammaktien zum Preis von 6,47 $ pro Aktie. Diese Transaktion stellt eine jährliche Zuteilung von eingeschränkten Aktien an nicht angestellte Direktoren dar und ist gemäß Regel 16b-3 ausgenommen.

Nach der Transaktion besitzt Hawkins nun insgesamt 204.018 Aktien direkt wirtschaftlich. Die Zuteilung der eingeschränkten Aktien wird mit dem früheren von 12 Monaten oder der nächsten Jahreshauptversammlung der Aktionäre fällig.

Wichtige Transaktionsdetails:

  • Transaktionstyp: Erwerb (Formular 4)
  • Aktienart: Stammaktien
  • Transaktionswert: Ca. 185.100 $
  • Eigentumsform: Direkt
  • Einreichungsdatum: 28. Juni 2025
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HAWKINS WILLIAM A

(Last) (First) (Middle)
1775 WEST OAK COMMONS COURT

(Street)
MARIETTA GA 30062

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MIMEDX GROUP, INC. [ MDXG ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/18/2025 A 28,609(1) A $6.47 204,018 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders
Remarks:
/s/ William F. Hulse as attorney-in-fact for William A. Hawkins III 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many MDXG shares did William Hawkins acquire on June 18, 2025?

William Hawkins acquired 28,609 shares of MDXG common stock on June 18, 2025, as part of an annual restricted stock grant to non-employee directors at a price of $6.47 per share.

What is the vesting period for MDXG director's restricted stock grant in 2025?

The restricted stock grant vests upon the earlier of 12 months or the next annual meeting of shareholders, as specified in the Form 4 filing footnotes.

How many MDXG shares does William Hawkins own after the June 18, 2025 transaction?

Following the reported transaction, William Hawkins directly owns 204,018 shares of MDXG common stock, as indicated in Table I of the Form 4 filing.

What is William Hawkins' role at MDXG according to the Form 4?

According to the Form 4 filing, William Hawkins serves as a Director of MIMEDX GROUP, INC. (MDXG), as indicated by the 'X' marked in the Director box under Section 5 of the form.

Is William Hawkins' MDXG stock ownership direct or indirect?

William Hawkins' ownership of MDXG stock is Direct (D), as shown in Column 6 of Table I in the Form 4 filing.
Mimedx Group Inc

NASDAQ:MDXG

MDXG Rankings

MDXG Latest News

MDXG Latest SEC Filings

MDXG Stock Data

877.35M
144.97M
2.72%
69.9%
2.78%
Biotechnology
Surgical & Medical Instruments & Apparatus
Link
United States
MARIETTA